Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kory J. Lavine, Attila Kovacs, David M. Ornitz
Published in Volume 118, Issue 7
J Clin Invest. 2008; 118(7):2404–2414 doi:10.1172/JCI34561
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
Coronary blood vessel loss and tissue hypoxia lead to cardiac failure and cardiomyocyte cell death in hearts deficient in HH signaling.

(AD) H&E-stained sections of Smomer,sm22 hearts prior to day 0 (A) and after 3 (B), 4 (C), and 5 (D) days of tamoxifen treatment, revealing ventricular dilation beginning at day 4 of tamoxifen treatment. Original magnification, ×25. (EH) Immunofluorescence staining for PECAM, revealing decreased coronary vessel density beginning after 3 days of tamoxifen treatment (F) compared with baseline (E). Coronary blood vessel density continues to decline after the fourth (G) and fifth (H) days of treatment. Original magnification, ×400. (I and J) Quantification of the number of blood vessels/×100 field (I) and the number of blood vessels/myocyte (J), demonstrating continuous decline in vascular density at days 3, 4, and 5 compared with baseline. *P < 0.01 compared with day 0; **P < 0.01 compared with day 3; ***P < 0.01 compared with day 4. (KN) Hypoxyprobe staining revealing the presence of hypoxic tissue after days 4 and 5 of tamoxifen treatment (black arrows). (OR) TUNEL staining indicating that cardiomyocyte cell death occurs beginning after day 5 of tamoxifen treatment (black arrow). (SV) Trichrome staining demonstrating that fibrosis is first detected beginning on the fifth day of tamoxifen treatment (white arrow). Original magnification, ×200. (W) Schematic depicting the sequence of events that occurs following tamoxifen treatment of Smomer,sm22 mice.